Drug intelligence / Profile preview

CIB in vivo CAR-T Lentiviral Injection

Development stage: Phase 1
Lead developer: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
Administration: Intravenous

Overview

CIB in vivo CAR-T Lentiviral Injection is an experimental gene therapy designed to generate Chimeric Antigen Receptor (CAR) T-cells directly within a patient's body (*in vivo*). Developed by the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences, this approach utilizes a lentiviral vector administered via intravenous infusion. Unlike traditional *ex vivo* CAR-T therapies, which require complex cell harvesting and laboratory modification, this *in vivo* method aims to simplify the process by delivering the genetic instructions for the CAR directly to the patient's immune cells. It is currently being evaluated in Phase 1 clinical trials for the treatment of advanced malignant solid tumors.

Other names: CIB in vivo CAR-T Lentiviral Injection

Targets

CD20 (B-lymphocyte antigen CD20)CD7 (CD7 antigen)

Beyond the preview

Go deeper on CIB in vivo CAR-T Lentiviral Injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIB in vivo CAR-T Lentiviral Injection.

Explore the full profile